Emergent BioSolutions (NYSE:EBS) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Emergent BioSolutions (NYSE:EBS) in a research note issued to investors on Monday, Marketbeat reports. The brokerage issued a buy rating and a $15.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Saturday, December 28th. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th. Finally, Benchmark increased their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Trading Up 3.4 %

EBS stock opened at $9.56 on Monday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The stock has a market capitalization of $518.00 million, a price-to-earnings ratio of -2.33 and a beta of 1.59. The business has a fifty day moving average price of $9.22 and a 200 day moving average price of $8.94. Emergent BioSolutions has a fifty-two week low of $1.42 and a fifty-two week high of $15.10.

Hedge Funds Weigh In On Emergent BioSolutions

A number of hedge funds and other institutional investors have recently bought and sold shares of EBS. Federated Hermes Inc. lifted its stake in shares of Emergent BioSolutions by 1,314.0% in the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after purchasing an additional 253,960 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in Emergent BioSolutions in the third quarter valued at about $1,547,000. Headlands Technologies LLC acquired a new position in shares of Emergent BioSolutions during the 2nd quarter worth about $969,000. Oak Hill Advisors LP bought a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at about $9,296,000. Finally, Assenagon Asset Management S.A. raised its position in shares of Emergent BioSolutions by 74.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after acquiring an additional 316,700 shares during the period. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.